
Teva loses patent protection on lucrative MS treatment
pharmafile | August 25, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Copaxone, Mylan, Teva, multiple sclerosis
Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone (glatiramer acetate) were invalid.
Mylan had petitioned the US Patent Trial and Appeal Board for four of Teva’s patents relating to Copaxone to be removed. The agency is scheduled to issue a final decision on the third patent by September 1st, while one patent invalidation claim was turned down.
The drug generates around $4 billion a year in revenue for Teva, or 20% of their overall revenue. These patents specifically cover administering the drug in a 40-milligram dosage three times a week, and were due to expire in 2030.
The under-fire Mylan believes that, because it brought the case, it will receive 180 days of marketing exclusivity upon regulatory approval. CEO Heather Bresch calls the ruling “comprehensive, well-reasoned and highly persuasive to detailing the bases for the invalidity.”
Teva, however, has indicated that it will appeal the decision. This, however, may engage the courts in a lengthy process.
CEO Erez Vigogman says: “We are prepared to defend the full suite of our intellectual property through the PTAB and the US courts regardless of the time required.”
Sean Murray
Related Content

Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

Sanofi shares results from phase 2 trial for frexalimab in MS treatment
Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for …

Sanofi and Teva partner for development of inflammatory bowel disease treatment
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …






